Stunning new research sheds light on daily cannabis consumption trends among middle-aged adults in the UK.

Lawmakers direct VA and FDA to explore cannabis for pain relief and psychedelics, while stressing the need for stricter regulation of cannabinoid food additives.

We proclaim our support for veterans, yet complex rules and federal restrictions continue to hinder their access to medical cannabis.

This groundbreaking dataset analyzes over 25,000 psychedelic support interactions, revealing essential insights into navigating challenging experiences.

Dive into the groundbreaking winners and therapeutic innovations from the inaugural High Times Medical Cannabis Cup Argentina 2026 event.

Explore Usona's psilocybin NDA for depression and FDA's approval of NRx's generic ketamine, alongside critical implications for the DC/MD/VA region.

The nonprofit Usona Institute has submitted its NDA for psilocybin, escalating competition with Compass Pathways in mental health treatment advancement.

Compass Pathways reveals its timeline for psilocybin treatment’s new drug application, targeting commercial availability by 2027.

Forty-six US veterans and first responders journeyed to Costa Rica for a transformative week of ayahuasca ceremonies and trauma therapy.

The DEA's federal registration of 900+ state-licensed dispensaries marks a pivotal change in patient access to medical cannabis.

A groundbreaking clinical study highlights how a single dose of psilocybin can rapidly alleviate depression, reshaping the landscape of mental health treatments.

An in-depth look at GrowHealthy's Florida dispensary network, medical delivery services, and insights for DMV cannabis consumers.

Final briefs submitted in administrative hearings on marijuana rescheduling as the DEA and opponents clash over federal evaluation processes.

A detailed review of 610 public comments submitted to the FDA's psychedelics docket reveals a mix of broad support and critical debates over therapy mandates, trial design, and patient access.

Federal scrutiny evolves as 900+ medical cannabis dispensaries secure official registrations, paving the way for a new era in cannabis regulation.

FDA and ARPA-H researchers unveil vital frameworks, REMS proposals, and safety challenges surrounding emerging psychedelic medicines.

Americans for Safe Access spotlights innovators, researchers, and organizations advancing cannabis safety and patient protections nationwide.

New York greenlights a groundbreaking clinical trial of a THC-based oral solution, VER-01, targeting chronic sciatica pain—a move with national medical cannabis implications.

The FDA outlines its ibogaine trial vision, Compass Pathways reveals pricing and slow rollout plans, and early healthcare leaders weigh in—here’s what DMV readers need to know.

An evidence-based examination of THC delivery methods, CBD dosing protocols, therapeutic mechanisms, and legal frameworks across DC and Virginia.